share_log

Duopharma Q3 PAT Up 60% To RM15.5 Million

Duopharma Q3 PAT Up 60% To RM15.5 Million

多發製藥第三季度淨利潤增長60%,達到1550萬令吉
Business Today ·  11/08 23:05

Duopharma Biotech Berhad saw strong growth in the third quarter ended 30 September 2024, with a revenue of RM208.73 million in the quarter, taking the cumulative revenue for FY2024 to date to RM620.02 million. The year-to-date revenue for FY2024 maintained a growth trajectory, up 15.4% from the RM537.23 million recorded in the same period last year it said.

Duopharma Biotech Berhad在截至2024年9月30日的第三季度實現了強勁增長,該季度的收入爲20873萬令吉,使 FY2024 迄今爲止的累計收入達到62002萬令吉。它表示,FY2024 今年迄今爲止的收入保持了增長軌跡,較去年同期的53723萬令吉增長了15.4%。

For the current quarter, PAT increased 60% to RM15.5 million compared to RM8.9 million recorded in the previous quarter.

在本季度,PaT增長了60%,至1550萬令吉,而上一季度的收入爲890萬令吉。

Meanwhile, the cumulative profit before tax (PBT) and profit after tax (PAT) across the three quarters rose 11.3% and 7.7% respectively. The robust double-digit growth the group said was primarily driven by higher sales across key sectors,
particularly the public health segment. The sales performance also offset increased operational costs associated with the newly completed K3 facility and higher finance costs, thus generating growth in PBT and PAT in the period.

同時,三個季度的累計稅前利潤(PBT)和稅後利潤(PAT)分別增長了11.3%和7.7%。該集團表示,強勁的兩位數增長主要是由關鍵領域的銷售增長推動的,
尤其是公共衛生部門。銷售業績還抵消了與新建的K3設施相關的運營成本和更高的財務成本,從而推動了同期PbT和PaT的增長。

In Q3 FY2024, Duopharma Biotech paid an interim dividend of 1.0 sen per share (2023: first interim dividend of 0.5 sen per share) equivalent to RM9.62 million (2023:RM 4.81 million) in respect of financial year ending 31 December 2024. The Directors did not recommend an interim dividend for the current quarter ended 30 September 2024.

在 FY2024 第三季度,Duopharma Biotech派發了截至2024年12月31日的財政年度每股1.0仙的中期股息(2023年:首次中期股息每股0.5仙),相當於962萬令吉(2023年:481萬令吉)。董事們沒有建議在截至2024年9月30日的本季度派發中期股息。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論